Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Journal of Biomedical and Techno Nanomaterials
Miksusanti Miksusanti
Universiti Sriwijaya
Biochemistry, Genetics & Molecular Biology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Design of Short Peptides as Targeted Protein Inhibitors for Alzheimer’s Disease Miksusanti Miksusanti; Faisal Razak; Nurul Huda; Muntasir Muntasir
Journal of Biomedical and Techno Nanomaterials Vol. 1 No. 3 (2024)
Publisher : Yayasan Adra Karima Hubbi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.70177/jbtn.v1i3.1757

Abstract

Alzheimer's disease is a neurodegenerative disorder marked by cognitive decline and memory loss, primarily caused by the aggregation of amyloid-beta and tau proteins in the brain. Conventional treatments offer limited benefits, emphasizing the need for new therapeutic strategies. To design and evaluate short peptides as targeted protein inhibitors to prevent the aggregation of amyloid-beta and tau proteins, aiming to halt or reverse the progression of Alzheimer's disease. The study employed computational modeling to design peptides, followed by in vitro assays for initial screening, and in vivo tests using transgenic mouse models to assess therapeutic efficacy and safety. Techniques included mass spectrometry, HPLC, and behavioral tests for cognitive function. Designed peptides demonstrated high binding affinity and specificity for amyloid-beta and tau proteins, reducing aggregation by 70% in vitro. In vivo studies showed significant reductions in amyloid plaques and tau tangles, with improved cognitive performance in treated mice. Peptides effectively crossed the blood-brain barrier and accumulated in target brain regions. The findings support the potential of short peptides as a novel therapeutic approach for Alzheimer's disease, warranting further research and clinical trials to validate their efficacy and safety in human subjects.
Development of Lipid Nanoparticles for Delivery of siRNA as Gene Therapy for Lung Cancer Miksusanti Miksusanti; Rafiullah Amin; Amir Raza
Journal of Biomedical and Techno Nanomaterials Vol. 1 No. 3 (2024)
Publisher : Yayasan Adra Karima Hubbi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.70177/jbtn.v1i3.1758

Abstract

Lung cancer remains a significant health challenge with high mortality rates, necessitating innovative treatment approaches. Lipid nanoparticles (LNP) offer a promising platform for the delivery of small interfering RNA (siRNA) as gene therapy to target specific oncogenes in lung cancer cells. To develop and optimize LNPs for efficient siRNA delivery, improving gene silencing efficiency and therapeutic outcomes in lung cancer treatment. The study involved in vitro and in vivo experiments to characterize the LNPs, evaluate gene silencing efficiency, and assess therapeutic efficacy. LNPs were formulated with specific lipid compositions and tested on lung cancer cell lines and murine models. Optimized LNP formulations demonstrated high siRNA encapsulation efficiency (>85%), stable particle size (80-120 nm), and suitable zeta potential (-30 to -50 mV). In vitro studies showed over 70% gene silencing efficiency, while in vivo experiments indicated significant tumor growth inhibition and improved survival rates in murine models. Biodistribution studies confirmed targeted delivery to lung and tumor tissues with minimal off-target effects. The study highlights the potential of LNP-siRNA therapy as an effective and specific treatment for lung cancer. Further research and clinical trials are needed to validate these findings and optimize the delivery system for clinical use.  
Co-Authors Amir Raza Faisal Razak Muntasir, Muntasir Nurul Huda Rafiullah Amin